MFN2 and lung cancer: Consistent with this, Xu et al. showed that patients with low Mfn2 levels had poorer prognoses, indicating more aggressive tumors, and they demonstrated that Mfn2 loss enhanced tumor growth in breast and lung cancer xenograft systems [86].